

## Original Article



## Effectiveness of Pentavalent Rotavirus Vaccine — a Propensity Score Matched Test Negative Design Case-Control Study Using Medical Big Data in Three Provinces of China

Yuexin Xiu<sup>1,2</sup>, Lin Tang<sup>1,2</sup>, Fuzhen Wang<sup>1,2</sup>, Lei Wang<sup>3</sup>, Zhen Li<sup>4</sup>, Jun Liu<sup>5</sup>, Dan Li<sup>3</sup>, Xueyan Li<sup>4</sup>, Yao Yi<sup>5</sup>, Fan Zhang<sup>3</sup>, Lei Yu<sup>6</sup>, Jingfeng Wu<sup>5</sup>, and Zundong Yin<sup>1,2,#</sup>

1. National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China; 2. National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center for Disease Control and Prevention; 3. Hubei Provincial Center for Disease Control and Prevention, Wuhan, China; 4. Beijing Municipality Chaoyang District Center for Disease Control and Prevention, Chaoyang District, Beijing, China; 5. Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China; 6. Department of Hospital Infection Management and Disease Prevention and Control, Children's Hospital Affiliated to Capital Institute of Pediatrics, Beijing, China

### Abstract

**Objective** The objective of our study was to evaluate the vaccine effectiveness (VE) of the pentavalent rotavirus vaccine (RV5) among < 5-year-old children in three provinces of China during 2020-2024 via a propensity score-matched test-negative case-control study.

**Methods** Electronic health records and immunization information systems were used to obtain data on acute gastroenteritis (AGE) cases tested for rotavirus (RV) infection. RV-positive cases were propensity score matched with RV-negative controls for age, visit month, and province.

**Results** The study included 27,472 children with AGE aged 8 weeks to 4 years at the time of AGE diagnosis; 7.98% (2,192) were RV-positive. The VE (95% confidence interval, *CI*) of 1-2 and 3 doses of RV5 against any medically attended RV infection (inpatient or outpatient) was 57.6% (39.8%, 70.2%) and 67.2% (60.3%, 72.9%), respectively. Among children who received the 3rd dose before turning 5 months of age, 3-dose VE decreased from 70.4% (53.9%, 81.1%) (<5 months since the 3rd dose) to 63.0% (49.1%, 73.0%) ( $\geq 1$  year since the 3rd dose). The three-dose VE rate was 69.4% (41.3%, 84.0%) for RVGE hospitalization and 57.5% (38.9%, 70.5%) for outpatient-only medically attended RVGE.

**Conclusions** Three-dose RV5 VE against rotavirus gastroenteritis (RVGE) in children aged < 5 years was higher than 1-2-dose VE. Three-dose VE decreased with time since the 3rd dose in children who received the 3rd dose before turning five months of age, but remained above 60% for at least one year. VE was higher for RVGE hospitalizations than for medically attended outpatient visits.

**Key words:** . Rotavirus vaccine; Vaccine effectiveness; Test-negative design; Propensity score matching

*Biomed Environ Sci*, 2025; 38(x): 1-12

doi: [10.3967/bes2025.056](https://doi.org/10.3967/bes2025.056)

ISSN: 0895-3988

[www.besjournal.com](http://www.besjournal.com) (full text)

CN: 11-2816/Q

Copyright ©2025 by China CDC

#Correspondence should be addressed to Zundong Yin, Researcher at the Chinese Center for Disease Control and Prevention, Director of the National Immunization Program of the Chinese Center for Disease Control and Prevention ([yinzd@chinacdc.cn](mailto:yinzd@chinacdc.cn))

Biographical note of the first author: Yuexin Xiu, master degree, majoring in vaccine and immunology, E-mail: [xiuyx@chinacdc.cn](mailto:xiuyx@chinacdc.cn)

## INTRODUCTION

Rotavirus gastroenteritis (RVGE) is caused by rotavirus (RV) infection and is the leading cause of severe dehydrating gastroenteritis among infants and young children globally<sup>[1]</sup>. RV is mainly transmitted through the fecal-oral route and is characterized by vomiting, diarrhea, and fever<sup>[2]</sup>. Before the introduction of the RV vaccine in 2006, RVGE was estimated to cause over 500 000 deaths and 2 million hospitalizations of children worldwide annually<sup>[3]</sup>. Between 2007 and 2012, *G1P[8]*, *G2P[4]*, *G3P[8]*, *G4P[8]*, *G9P[8]*, and *G12P[8]* strains accounted for more than 70% of global RV genotypes<sup>[4]</sup>.

In China, prior to the launch of the RV vaccine in 2000, RVGE accounted for 28% and 46% of diarrhea-related outpatient and inpatient cases in children aged <5 years<sup>[5]</sup>. Owing to improvements in socioeconomic status and hygiene, along with the introduction of RV vaccines, RVGE mortality in 2012 was 70% lower than that in 2003<sup>[6]</sup>, and the proportion of RVGE among all infectious diarrhea cases declined<sup>[7]</sup>. However, National Notifiable Diseases Reporting System (NNDRS) data have shown an upward trend in RVGE in recent years<sup>[8]</sup>. A meta-analysis found that the overall prevalence of RVGE in stool samples obtained in surveillance settings in China from 2019 to 2023 was 19%, with *G9P[8]* being the predominant genotype in G-P combinations, accounting for 78% of RV infections, followed by *G8P[8]* (31%) and *G3P[8]* (8%) genotypes<sup>[9]</sup>.

By 2022, 121 countries and regions will include RV vaccines in their immunization programs, with a final dose coverage of 51% by 2023<sup>[10]</sup>. As the earliest World Health Organization-prequalified RV vaccine (in 2008), the oral pentavalent reassortant rotavirus attenuated live vaccine (RotaTeq, RV5) has shown good safety with vaccine effectiveness (VE) levels of 90% and 45% among children under five years in low and high mortality countries, respectively<sup>[3]</sup>. RV5 was licensed in China in 2018<sup>[11]</sup>, and coverage among children aged <5 years was approximately 20%–40% for this non-program (family paid) vaccine<sup>[11,12]</sup>. According to immunization information systems in the study areas, from 2021 to 2023, the average rotavirus vaccination rates were 32% in Guangdong, 42% in Wuhan (Hubei), and 30% in Chaoyang (Beijing).

Previous real-world studies in China found that the RV5 VE against RVGE in children aged < 5 years varied between 30% and 90%<sup>[13-15]</sup>. These studies

generally focused on a single region and had modest sample sizes. Medical health big data platforms such as hospital information systems (HISs) and electronic health records (EHRs) are frequently used in real-world studies<sup>[16-18]</sup>. Medical big data platforms can enhance the representativeness and generalizability of research findings by providing access to well-characterized populations across diverse regions and tiers of healthcare institutions<sup>[19]</sup>. Unlike previous single-region studies, research based on healthcare big data platforms requires the use of statistical methods, such as propensity score matching (PSM), to control for bias and confounding introduced by multi-source data<sup>[20]</sup>. Furthermore, Test-negative design (TND) case-control studies<sup>[21]</sup> that can mitigate biases have been widely used to evaluate the VEs of influenza<sup>[22]</sup>, coronavirus Disease 2019 (COVID-19)<sup>[23]</sup>, and RV vaccines<sup>[13,24]</sup>. This methodology effectively mitigates confounding and bias from differences in healthcare-seeking behaviors/access and differences in vaccination and community-level disease risk between cases and controls<sup>[25]</sup>.

We obtained data from HISs and EHRs in three areas of China and used a PSM-TND study to determine more representative and less biased VE estimates than those previously available in China. Herein, we report the methods and results of our study.

## MATERIALS AND METHODS

### Setting, Data Sources, and Design

This study was conducted in one region of northern China (Chaoyang District, Beijing) and two regions of southern China (Guangdong Province and Wuhan City, Hubei Province). Three areas were selected for data availability analysis. We obtained demographic, clinical diagnostic, and pathogen detection information from children aged < 5 years who were brought to medical attention for acute gastroenteritis (AGE) between January 1, 2020, and April 30, 2024, and were tested for RV. Data were sourced from the multipoint trigger platform of Guangdong (a big data platform for data sharing among medical institutions across the province), supplemented with additional inpatient data from Guangdong Maternal and Children's Hospital, the HIS of one hospital in Chaoyang District, Beijing, and two hospitals in Wuhan (all 29 participating hospitals were tertiary hospitals). RV vaccination status was obtained through the respective immunization

program information systems by matching unique national identification (ID) numbers. The test-negative design case-control study is an efficient and accurate method for evaluating VE by comparing the vaccination ratio between RV-positive and RV-negative AGE subjects. PSM is a method used to calculate the probability of each individual receiving a certain treatment (or outcome) and then match the individuals in the treatment group (case group) and the control group based on this probability, making the two groups comparable in key variables. Our PSM-TND study used a 1:2 PSM of cases to controls to estimate VE against RV infection based on EHR data and vaccination information. Propensity scores were based on the enrollment age, visit month, and province.

### **Subjects**

Inclusion criteria for enrollment were: (1) age at visit between 8 weeks (two weeks after the earliest age for receiving the first dose of RV5) to 4 years; (2) with a diagnosis recorded in the EHR as one of the following (diagnostic name[ICD10 code]): other bacterial intestinal infections [A04](except antibiotic-associated colitis [A04.700x002]), viral and other specified intestinal infections [A08], bacterial intestinal infections (other and unspecified) [A09.000], infectious causes of gastroenteritis and colitis (other and unspecified) [A09.000x001], infectious gastroenteritis [A09.001], infectious colitis [A09.002], infectious diarrhea [A09.004], acute infectious gastroenteritis [A09.007]; and (3) tested for RV with polymerase chain reaction (PCR) nucleic acid testing or enzyme-linked immunosorbent assay (ELISA) antigen testing. Potential subjects whose rotavirus vaccination information was unclear after matching, who were out of the inclusion age range, who received their most recent dose less than 14 days before the AGE visit, or who were vaccinated out of compliance with the immunization schedule (see below) were excluded. For children with more than one AGE medical visit during the study period, we used the first visit for analysis.

### **Vaccination Status and Primary Outcomes**

The vaccination schedule included the 1st dose at 6-12 weeks of age, with an interval of 4-10 weeks between each dose, and the third dose before 32 weeks of age. We defined vaccination status as: 1-dose vaccinated if the child received a single dose between 6 weeks and 12 weeks of age and  $\geq 14$  days before the visit date; 2-dose vaccinated if the child received two doses, with the 2nd dose between 10

weeks and 22 weeks of age and  $\geq 14$  days before the visit date; 3-dose vaccinated if the child received three doses with the third dose between 14 weeks and 32 weeks of age and  $\geq 14$  days before the visit date.

We combined 1- and 2-dose vaccinated subjects because the number of children receiving fewer than three doses was relatively small. We calculated propensity score-matched (1:2 ratio of cases to controls) 1-2 dose and 3-dose RV5 VE against any medically attended RVGE infection (inpatient or outpatient), outpatient-only medically attended RVGE, and RVGE hospitalization.

### **Secondary Outcomes**

We estimated VE in 3-dose recipients by time since the third dose (< 5 months,  $\geq 5$  months – < 1 year, and  $\geq 1$  year between the last dose date and the visit date). To reduce the influence of vaccination age on VE (for example, VE in children who are younger when vaccinated may be lower because their immune system is less mature<sup>[26]</sup>), we calculated VE by time since the third dose separately for children who received the third dose before turning five months of age and children who received their third dose at five months of age or older.

### **Sensitivity Analyses**

Sensitivity analyses stratified by province were conducted using PSM for visit month and age.

### **Sample Size**

The target sample size was calculated using formulas (1)–(7), in which  $p_0$  and  $p_1$  represent the vaccination rates of the control and case groups, respectively. The target sample size was determined based on the maximum sample size required, assuming a VE of 50% as the predefined parameter for calculation, ensuring sufficient statistical power under the most conservative efficacy scenario<sup>[27,28]</sup>. Conservatively assuming a 1:4 case:control match to compensate for exclusion caused by issues such as missing data (estimated at 20%), and using  $\alpha = 0.05$ ,  $\mu_\alpha = 1.96$ ,  $\beta = 0.20$ ,  $\mu_\beta = 0.84$ , in the formula below, our minimum target sample size was 3 130. The final sample size was based on the number of subjects available on the data platforms during the study period and was greater than the minimum target sample size. The maximum ratio that reached equilibrium after PSM matching was 1:2, which was lower than the initial sample size calculation setting of 1:4 and represents a conservative match ratio.

$$n = \frac{[\mu_{\alpha}\sqrt{2pq} + \mu_{\beta}\sqrt{p_1q_1 + p_0q_0}]^2}{(p_1 - p_0)^2} \quad (1)$$

$$q_0 = 1 - p_0 \quad (2)$$

$$p_1 = p_0 \times OR / [1 + p_0 \times (OR - 1)] \quad (3)$$

$$q_1 = 1 - p_1 \quad (4)$$

$$p = (p_1 + p_0) / 2 \quad (5)$$

$$q = 1 - p \quad (6)$$

$$VE = (1 - OR) \times 100\% \quad (7)$$

### Statistical Analysis

Variables with non-normal distributions were reported as medians and interquartile ranges (IQRs), while the enumerated data were presented as numbers and percentages. Bivariate analyses were performed to assess the differences between cases and controls, and to identify potential confounders using the  $\chi^2$  test or Fisher's exact test. Patients in healthcare settings, who sought care for AGE symptoms, were categorized into case/control groups based on positive/negative rotavirus test results. We compared the RV vaccination rates between the two groups to evaluate the association between vaccination and RVGE<sup>[25]</sup>. To reduce the confounding bias caused by the separate sources of research subjects (different medical institutions in different regions), we used propensity score caliper matching to calculate a less biased VE. We divided the total population into an outpatient subgroup, an inpatient subgroup, and subgroup who received 0 or 3 doses (further divided into subgroups who received the 3rd dose before turning 5 months of age and after turning 5 months of age). PSM was conducted separately for the total population and the subgroups. We used logistic regression to

calculate the conditional probability of the study subjects being assigned to the case group or control group under potential confounding factors (age and visit month as continuous variables; province as a categorical variable (Guangdong, Beijing, Hubei); and an interaction term between age and province) and then balanced the distribution of these factors between the two groups within the total population and each subgroup<sup>[29]</sup>. We used a caliper value of 0.2 standard mean difference (SMD) between the two groups before and after matching, as calculated based on the mean and standard deviation (SD) of the two groups. SMD less than 0.1 is generally considered a balanced distribution. All tests were two-tailed, and statistical significance was set at  $P < 0.05$ .

Microsoft Office Excel 2019 (Redmond, WA, USA) was used to clean the data, and R statistics (4.3.1) was used to perform statistical analysis. PSM was performed using the MatchIt software package.

### Ethical Review

The study was approved by the Chinese Center for Disease Control and Prevention Institutional Review Board [(2024) No. 202406].

## RESULTS

A total of 97,950 patients with AGE were tested for RV during the study period. After excluding 70,478 potential subjects who did not meet the enrollment criteria, data for 27 472 children aged 8 weeks to 4 years at the visit date were included in the analytic dataset. In the 1:2 PSM-matches, 2,192 RV-positive cases were matched to 4,384 RV-negative controls; 1,779 outpatient cases were matched to 3,558 outpatient controls, and 413 inpatient cases were matched to 824 inpatient controls (one case could not be matched with two controls). Among those who received 0 or 3 doses, 2,108 cases were matched to 4,036 controls (for children who received the third dose before turning five months old), and 1,953 cases were matched to 3,906 controls (for children who received the third dose at five months of age or older) (Figure 1).

Among the 27,472 subjects in our analytic data set, 59.01% (16,211) were male; the median (IQR) age was 1.13 (0.61, 2.14) years; 7.98% (2 192) were rotavirus positive; 4.11% (1 129) received 1 vaccine dose, 3.97% (1 090) received 2 doses, and 27.59% (7,580) received 3 doses. The median (IQR) age was 0.9 (1.7, 3.0) years for outpatients versus 0.6 (1.1, 2.0) years for inpatients. After excluding cases

without corresponding symptom information, the median (IQR) diarrhea duration was 4 (2, 8) days (outpatients) vs. 5 (3, 7) days (inpatients), the median (IQR) maximum daily diarrheal episodes was 5 (4, 8) episodes (outpatients) vs. 7 (5, 10) episodes (inpatients), the median (IQR) vomiting duration was 1 (1, 2) days (outpatients) vs. 2 (1, 3) days (inpatients), the median (IQR) maximum daily vomiting episodes was 3 (2, 4) episodes (outpatients) vs. 2 (2, 4) episodes (inpatients). Statistically significant differences were observed in the province, age, patient source (inpatient/outpatient), visit month, vaccination dose, and time since the third dose between the case and control groups (Table 1).

### Propensity Score-matched RV5 VE in All Subjects

After 1:2 PSM based on enrollment age, visit month, province, and age\*province, there were no statistically significant differences in enrollment age, visit month, and province, except among children who received the third dose before turning five months old, with *SMDs* all below 0.1 (Table 2).


After PSM for enrollment age, visit month, province, and age\*province (interaction term), conditional logistic regression showed that the 3-dose VE (95% CI) point estimate of 67.2% (60.3%–72.9%) was higher than the 1-2 dose VE (95% CI) point estimate of 57.6 (39.8%–70.2%); however, the partially overlapping CIs indicated no statistically significant difference between these two

estimates (Table 3). Sensitivity analyses stratified by province yielded consistent results (Supplementary Table S2). The average interval between the 3rd dose and AGE diagnosis was 330 days for inpatients and 398 days for outpatients. Among children who received a third dose, VE among children who received a third dose before turning five months of age decreased by time since the third dose and remained  $> 61\% \geq 1$  year after the third dose, although the overlapping CIs suggest that the difference was not statistically significant (Table 4).

### Propensity Score-Matched Ve of Rv5 Stratified by Inpatient or Outpatient

There were significant differences in enrollment age, visit month, and province between the case and control groups before PSM. After 1:2 PSM for enrollment age, visit month, province, and age\*province, except among outpatients, all *SMDs* were below 0.1 (Table 2).

After PSM for enrollment age, visit month, province, and age\*province, conditional logistic regression showed that the point estimates for VE (95%CI) were higher against hospitalization (1 or 2 doses: 62.8% (-47.1%–90.6%); 3 doses: 69.4% (41.3%–84.0%)) than against outpatient visits [1 or 2 doses: 57.5% (38.9%–70.5%); 3 doses: 64.5% (56.6%–71.0%)], regardless of the number of doses. However, overlapping CIs indicate that these differences were not statistically significant (Table 3).



**Figure 1.** Study flow chart. Shown are the inclusions and exclusions of subjects, the propensity-score matchings between cases and controls, and the vaccination statuses of cases and controls.

**DISCUSSION**

We used a propensity-matched, test-negative-

design case-control study to estimate the effectiveness of the pentavalent RV5 among children aged < 5 years using electronic health record data

**Table 1.** Characteristics of children with AGE, prior to propensity score matching

Variable	Cases <i>N</i> (%)	Controls <i>N</i> (%)	$\chi^2$	<i>P</i> value
Province				
Guangdong	155 (7.07)	2,555 (10.11)	20.91	< 0.01
Beijing	627 (27.62)	6,982 (27.62)		
Hubei	1,410 (64.32)	15,743 (62.27)		
Age ( <i>t</i> =-24.62, <i>P</i> < 0.001)				
8 weeks - < 1 year-old	487 (22.22)	11,771 (46.56)	483.81	< 0.01
1 year - ≤4 years-old	1,705 (77.78)	13,509 (53.44)		
Sex				
Male	1,323 (60.36)	14,888 (58.89)	1.79	0.18
Female	869 (39.64)	10,392 (41.11)		
In-patient/out-patient				
In-patient	413 (18.84)	2,618 (10.36)	147.96	< 0.01
Out-patient	1,779 (81.16)	22,662 (89.64)		
Visit month				
Jan	227 (10.36)	1,618 (6.40)	1,355.84	< 0.01
Feb	296 (13.50)	1,611 (6.37)		
Mar	574 (26.19)	2,225 (8.80)		
Apr	374 (17.06)	2,342 (9.26)		
May	157 (7.16)	2,178 (8.62)		
Jun	94 (4.29)	2,480 (9.81)		
Jul	82 (3.74)	2,631 (10.41)		
Aug	84 (3.83)	2,439 (9.65)		
Sep	79 (3.60)	2,298 (9.09)		
Oct	67 (3.06)	2,253 (8.91)		
Nov	77 (3.51)	1,772 (7.01)		
Dec	81 (3.70)	1,433 (5.67)		
Doses administered				
0	1,853 (84.53)	15,820 (62.58)	424.13	< 0.01
1	34 (1.55)	1,095 (4.33)		
2	40 (1.82)	1,050 (4.15)		
3	265 (12.09)	7,315 (28.94)		
Time since the third dose				
< 5 months	61 (23.02)	2,357 (32.22)	17.62	< 0.01
5 months - < 1 year	83 (31.32)	2,479 (33.89)		
≥1 year	121 (45.66)	2,479 (33.89)		

**Note.** Jan, January; Feb, February; Mar, March; Apr, April; May, May; Jun, June; Jul, July; Aug, August; Sep, September; Oct, October; Nov, November; Dec, December.

**Table 2.** Characteristics of cases (RV positive) and controls (RV negative) before and after propensity matching\*

Variable	Before matching				After matching			
	Cases Mean (SD)	Controls Mean (SD)	P	SMD	Cases Mean (SD)	Controls Mean (SD)	P	SMD
Total group								
N	2,192	25,280			2,192	4,384		
Age	2.12 (1.28)	1.47 (1.17)	< 0.01	0.53	2.12 (1.28)	2.08 (1.36)	0.27	0.03
Visit month	4.49 (2.96)	6.51 (3.18)	< 0.01	0.66	4.49 (2.96)	4.41 (2.87)	0.32	0.03
Province			< 0.01	0.11			0.07	0.06
Guangdong	155 (7.07)	2,555 (10.11)			155 (7.07)	266 (6.07)		
Beijing	627 (28.60)	6,982 (27.62)			627 (28.60)	1,182 (26.96)		
Hubei	1,410 (64.32)	15,743 (62.27)			1,410 (64.32)	2,936 (66.97)		
0 and 3 dose group								
Third dose at < 5 months of age								
N	2,018	20,252			2,018	4,036		
Age	2.18 (1.27)	1.57 (1.21)	< 0.01	0.49	2.18 (1.27)	2.15 (1.36)	0.40	0.02
Visit month	4.37 (2.91)	6.48 (3.19)	< 0.01	0.69	4.37 (2.91)	4.34 (2.87)	0.70	0.01
Province			< 0.01	0.12			0.49	0.03
Guangdong	131 (6.49)	1,981 (9.78)			131 (6.49)	235 (5.82)		
Beijing	583 (28.89)	5,765 (28.47)			583 (28.89)	1,145 (28.37)		
Hubei	1,304 (64.62)	12,506 (61.75)			1,304 (64.62)	2,656 (65.81)		
Third dose at ≥5 months of age								
N	1,953	18,703			1,953	3,906		
Age	2.21 (1.27)	1.62 (1.24)	< 0.01	0.47	2.21 (1.27)	2.18 (1.35)	0.38	0.02
Visit month	4.31 (2.85)	6.45 (3.18)	< 0.01	0.71	4.31 (2.85)	4.27 (2.81)	0.53	0.02
Province			< 0.01	0.14			0.04	0.07
Guangdong	124 (6.35)	1,885 (10.08)			124 (6.35)	206 (5.27)		
Beijing	560 (28.67)	5,194 (27.77)			560 (28.67)	1,044 (26.73)		
Hubei	1,269 (64.98)	11,624 (62.15)			1,269 (64.98)	2,656 (68.00)		
Inpatient group								
N	413	2,618			413	824		
Age	2.57 (1.27)	1.86 (1.24)	< 0.01	0.57	2.57 (1.27)	2.47 (1.28)	0.19	0.08
Visit month	3.43 (1.97)	6.25 (3.30)	< 0.01	1.04	3.43 (1.97)	3.37 (1.99)	0.63	0.03
Province			< 0.01	0.23			0.41	0.08
Guangdong	35 (8.47)	396 (15.13)			35 (8.47)	53 (6.42)		
Beijing	2 (0.48)	34 (1.30)			2 (0.48)	4 (0.48)		
Hubei	376 (91.04)	2,188 (83.58)			376 (91.04)	769 (93.10)		
Out-patient group								
N	1,779	22,662			1,779	3,558		
Age	2.01 (1.25)	1.42 (1.15)	< 0.01	0.49	2.01 (1.25)	2.00 (1.36)	0.79	0.01
Visit month	4.73 (3.10)	6.54 (3.17)	< 0.01	0.58	4.73 (3.10)	4.70 (3.01)	0.77	0.01
Province			< 0.01	0.13			0.02	0.08
Guangdong	120 (6.75)	2,159 (9.53)			120 (6.75)	183 (5.14)		
Beijing	625 (35.13)	6,948 (30.66)			625 (35.13)	1,196 (33.61)		
Hubei	1,034 (58.12)	13,555 (59.81)			1,034 (58.12)	2,179 (61.24)		

**Note.** \* PSM was based on the enrollment age and visit month. SD, standard deviation; SMD, standard mean difference.

from 29 hospitals in three provinces of China. Three doses of RV5 provided greater protection against RVGE (VE = 67.2%) than one or two doses. VE against RV infection at least one year after the third dose remained above 61%. VE was greater for RVGE hospitalization than for medically attended RVGE outpatient visits (VE = 69.4% vs. VE = 64.5%).

The 3-dose PSM-VE of 67.2% found in our study

was lower than VE findings in the United States and Europe (94.5% against hospitalization and emergency care)<sup>[30]</sup> but higher than VE findings from South Asia (48.3% against severe RVGE)<sup>[31]</sup>. The effectiveness was similar to the efficacy findings from a phase III randomized clinical trial (70%) in China<sup>[32]</sup>, lower than the VE study findings in Shanghai (85%)<sup>[13]</sup> and Taiwan (93%)<sup>[14]</sup>, and higher

**Table 3.** Vaccine effectiveness of RV5 against RVGE stratified by clinical outcomes.

	Cases <i>n</i> (%)	Controls <i>n</i> (%)	Propensity score-matched OR (95%CI)	Propensity score-matched VE (95%CI)
Any medically attended RVGE infection				
Vaccination dose	<i>n</i> = 2,192	<i>n</i> = 4,384		
0 doses	1,853 (82.91%)	2,978 (66.62%)		
1 or 2 dose	39 (1.74%)	109 (2.44%)	0.42 (0.30–0.60)	57.6 (39.8–70.2)
3 doses	298 (13.33%)	1,258 (28.14%)	0.33 (0.27–0.40)	67.2 (60.3–72.9)
In-patient group				
Vaccination doses	<i>n</i> = 413	<i>n</i> = 824		
0 doses	391 (94.67%)	695 (84.34%)		
1 or 2 doses	5 (1.21%)	20 (2.43%)	0.37 (0.09–1.47)	62.8 (–47.1–90.6)
3 doses	17 (4.12%)	109 (13.23%)	0.31 (0.16–0.59)	69.4 (41.3–84.0)
Out-patient group				
Vaccination dose	<i>n</i> = 1,779	<i>n</i> = 3,558		
0 doses	1,462 (82.18%)	2,403 (67.54%)		
1 or 2 doses	69 (3.88%)	179 (5.03%)	0.43 (0.30–0.61)	57.5 (38.9–70.5)
3 doses	248 (13.94%)	976 (27.43%)	0.35 (0.29–0.43)	64.5 (56.6–71.0)

**Note.** OR, odds ratio; VE, vaccine effectiveness.

**Table 4.** Vaccine effectiveness of 3 doses of RV5 against RVGE stratified by the time since the 3rd dose.

	Cases <i>n</i> (%)	Controls <i>n</i> (%)	Propensity score-matched OR (95%CI)	Propensity score-matched VE (95%CI)
Received the 3rd dose at < 5–months–old group				
Time since the 3rd dose	<i>n</i> = 2,018	<i>n</i> = 4,036		
0 doses	1,853 (91.82%)	3,333 (82.58%)		
< 5 months	39 (1.93%)	191 (4.73%)	0.30 (0.19–0.46)	70.4 (53.9–81.1)
5 months – < 1 year	53 (2.63%)	208 (5.15%)	0.35 (0.24–0.50)	65.4 (49.8–76.1)
≥1 year	73 (3.62%)	304 (7.53%)	0.37 (0.27–0.51)	63.0 (49.1–73.0)
Received the 3rd dose at ≥5–months–old group				
Time since the 3rd dose	<i>n</i> = 1,953	<i>n</i> = 3,906		
0 doses	1,853 (94.88%)	3,378 (86.48%)		
< 5 months	22 (1.13%)	124 (3.17%)	0.31 (0.17–0.54)	69.3 (45.9–82.6)
5 months – < 1 year	30 (1.54%)	166 (4.25%)	0.25 (0.15–0.41)	75.1 (58.7–85.0)
≥1 year	48 (2.46%)	238 (6.09%)	0.38 (0.26–0.56)	61.7 (44.2–73.8)

**Note.** OR, odds ratio; VE, vaccine effectiveness.

than that in a VE study in Guangdong province (64.1%)<sup>[15]</sup>. There are several possible explanations for this discrepancy. First, RV5 VE is apparently higher in regions with higher vaccination rates<sup>[1,33]</sup>. RV5 coverage in China was variable, with relatively higher coverage in regions with higher levels of socioeconomic development. Second, studies with small sample sizes may introduce sampling errors and instability in the results<sup>[34]</sup>. The sample size of our study was significantly larger than that of the other two studies because of access to a population-based data platform. Third, differences in VE may be related to circulating RV genotypes. The most prevalent G-P combination among children aged <5 years changed from *G9P[8]*<sup>[35-37]</sup> to *G8P[8]* in Guangdong<sup>[15]</sup>, Beijing<sup>[38]</sup>, and Hubei<sup>[39]</sup> after 2020. Our study showed that RV5 has a protective effect against the *G8P[8]* and *G9P[8]* genotypes observed in the three regions of our study. Since RV5 consists of *G1*, *G2*, *G3*, *G4*, and *P1A[8]*, there may be cross-protection against the *G8* genotype, which is not included in the vaccine<sup>[15]</sup>. Finally, environmental enteropathy, a relatively common subclinical disease in developing countries, is associated with poverty and unsanitary living environments and can affect the immune response to oral RV vaccines<sup>[40]</sup>.

Consistent with most real-world RV VE studies<sup>[41]</sup>, we found that the 3-dose VE<sup>[42]</sup> was greater than the 1-2-dose VE. However, these findings are inconsistent. For example, the 3-dose VE in 8-month-old children was shown to be 89%-94% in the United States, which was lower than the 2-dose VE (90%-100%)<sup>[43]</sup>. Another study found no significant difference between the 3-dose VE (87%) and 2-dose VE (88%) in children aged < 4 years in the United States<sup>[44]</sup>. Partial RV5 vaccination provides significant protection<sup>[3,45]</sup>, but full vaccination generally has greater protection, as we found.

Although 3-dose VE decreased by time since the third dose in children who received a third dose before turning 5 months old, the VE point estimate remained > 61% ≥ 1 year after the third dose, suggesting that RV5 VE has good persistence in young children. Owing to the late launch of RV5 in China, our study was unable to investigate the duration of protection provided by the vaccine over a longer period. However, a long-term US study demonstrated that strong long-term RV5 protection persisted for seven years after vaccination<sup>[46]</sup>. The decline in VE might not be entirely caused by declining vaccine-induced antibodies. Some of the decrease could be explained by a higher incidence of natural asymptomatic and mild infections (and thus

preferential immune boosting) among unvaccinated controls compared to vaccine recipients, the so-called spurious waning<sup>[21]</sup> caused by leaky vaccines<sup>[47]</sup>.

Our study found that VE against RVGE hospitalization was greater than VE against medically attended outpatient RVGE, and hospitalized cases demonstrated consistently higher median values than outpatients for diarrhea duration, maximum daily diarrheal episodes, and vomiting duration (not statistically tested due to the limited sample size). This finding is consistent with those of previous studies<sup>[48]</sup>, as RV5 has been shown to be more protective against severe RVGE<sup>[3,14,49]</sup>. VE against severe RVGE and hospitalization were similar, and both were greater than VE against RV infection<sup>[50]</sup>. Our study found that RV5 provided better protection against RVGE hospitalizations in patients with more severe symptoms.

Our study has several strengths. By using big data platforms from three geographically distant provinces, we were able to put together a large sample size, enhancing precision and representativeness. Our use of PSM in this TND case-control study likely reduced the influence of confounding factors, making the results more reliable.

Our study had several limitations. Our study was observational; therefore, we reported associations rather than causal ones. The data source for Guangdong is a multi-point trigger platform, including data targeting various age groups, while the data in Beijing and Hubei come from children's hospitals targeting younger ages. This heterogeneity in hospitals and geographic locations may be associated with differences in healthcare-seeking behaviors and introduce an unknown bias into the results; however, we used PSM to mitigate key potentially confounding variables, including provinces. The hospitals in the study did not conduct RV genotype testing, which precluded genotype analysis. However, based on genotype research in China, we believe that our study estimates the protective effects of RV5 against locally prevalent genotypes. We did not conduct a questionnaire survey and could not obtain parental demographic characteristics (e.g., socioeconomic status and breastfeeding practices) that could serve as potential confounding factors. The small sample size of patients receiving either 1 or 2 doses prevented a meaningful comparison between the two dosing regimens. The limited number of cases with symptom information precluded the evaluation of

the VE of RV5 by symptoms owing to insufficient sample size. However, VE against hospitalized RVGE can partially compensate for this deficiency, as inpatient status represents severe RVGE because admitted children must have been ill enough to require hospitalization. We were unable to assess VE in rural China because the RV vaccine coverage is too low in rural areas to conduct a reasonably precise VE study. Urban-rural stratification could not be matched in the analytical dataset because of the systematic de-identification protocols implemented, which removed all personally identifiable information (including residential classification markers derived from ID numbers) during data preprocessing. This limitation of available data makes it impossible to provide separate VE analysis for rural and urban settings or for economically disadvantaged areas where the disease burden may be higher. Current research indicates that the VE of RV vaccines is generally better in urban areas than in rural areas, primarily due to the influence of vaccination coverage, sanitation conditions, and medical resources<sup>[3,51]</sup>. Such limitations underscore the difficulty of generalizing the results to rural settings and the desirability of conducting VE studies in rural and economically disadvantaged settings. Our study was unable to assess the duration of protection over an extended period because of limited data; therefore, studies with longer follow-up periods are needed. Our study was conducted during the COVID-19 pandemic, and public health and social measures likely decreased the circulation of rotaviruses. However, this reduction in circulation is unlikely to be associated with the RV vaccination status.

We found that RV5 VE in our real-world study was lower than the vaccine efficacy in clinical trials and observational studies in developed countries and domestic regions with high economic levels. The coverage rate in the present study was low (30 %). The influence of coverage in relation to herd immunity on VE has been described in studies in Belgium, Finland, and the United Kingdom (UK)<sup>[52]</sup>. Studies exploring the impact of coverage on the VE may shed light on this phenomenon. In general, TND studies are the most efficient, with coverages between approximately 20% and 80%, as observed in our study.

Our study showed that the RV5 vaccine has a strong protective effect in Chinese children aged < 5 years, with good persistence up to 1 year after the completion of vaccination. VE was greater during hospitalization than during medically attended RVGE

outpatient visits. Full 3-dose series VE was greater than that after partial vaccination. Families and providers should strive to complete the vaccination series as recommended.

**Funding** This study was supported by two grants: the Study on Vaccine Application Evaluation Strategies and Capacity Building (INV-006373) and the National Key R&D Program of China (2024YFC2310604). The funders played no role in the study design, data collection and analysis, decision to publish, or manuscript preparation.

**Competing Interests** The authors declare that they have no competing financial interests or personal relationships that may have influenced the work reported in this study.

**Ethics** This study was approved by the Chinese Center for Disease Control and Prevention Institutional Review Board [(2024) No. 202406].

**Authors' Contributions** Yuexin Xiu: Conceptualization, Methodology, Formal analysis, Writing-original draft, Project administration. Lin Tang, Fuzhen Wang, Zundong Yin: Writing-review and editing, Supervision, Project administration, Funding acquisition. Lei Wang, Zhen Li, Jun Liu, Dan Li, Xueyan Li, Yao Yi, Fan Zhang, Lei Yu, Jingfeng Wu: Data collection and curation.

**Acknowledgements** We thank Dr. Lance Rodewald from the Chinese Center for Disease Control and Prevention for his comments and English language editing. We also thank Wanjun Luo from the Wuhan Children's Hospital, Tongji College Huazhong University of Science & Technology, Wuhan, China; Liang Bao from the Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China; and Yangyang Wu from the Department of Hospital Infection Management and Disease Prevention and Control, Children's Hospital Affiliated to the Capital Institute of Pediatrics, Beijing, China, for their contributions to data collection.

**Data Sharing** The datasets analyzed in the current study are not publicly available because of the confidentiality of patient information. The Supplementary Materials will be available in [www.besjournal.com](http://www.besjournal.com).

**Disclaimer** The findings and conclusions of this report are those of the authors and do not necessarily represent the official position of the Chinese Center for Disease Control and Prevention, Guangdong Provincial Center for Disease Control and Prevention, Hubei Provincial Center for Disease

Control and Prevention, or Beijing Municipality Chaoyang District Center for Disease Control and Prevention.

Received: February 13, 2025;

Accepted: May 7, 2025

## REFERENCES

- Duan ZJ, Li JS, Zhang J, et al. Expert consensus on immunoprophylaxis of childhood rotavirus gastroenteritis (2024 version). *Chin J Vaccin Immun*, 2024; 30, 95–126. (In Chinese)
- Centers for Disease Control and Prevention(US). Transmission of rotavirus. <https://www.cdc.gov/rotavirus/about/index.html>. [2024-06-12]
- World Health Organization. Rotavirus vaccines: WHO position paper-July 2021. *Weekly Epidemiol Rec*, 2021; 96, 301–20.
- World Health Organization. WHO immunological basis for immunization series: module 21: rotavirus. <https://www.who.int/publications/i/item/who-immunological-basis-for-immunization-series-module-21-rotavirus>. [2024-06-13]
- Fang ZY, Zhang LJ, Tang JY, et al. Rotavirus diarrhea among Children in Lulong County, Hebei Province, China. *Chin J Virol*, 2005; 21, 21–6. (In Chinese)
- Zhang J, Duan ZJ, Payne DC, et al. Rotavirus-specific and overall diarrhea mortality in Chinese Children Younger than 5 years: 2003 to 2012. *Pediatr Infect Dis J*, 2015; 34, e233–7.
- Feng LR, Zhao Q. Analysis of bacterial spectrum and drug resistance changes in children with infectious diarrhea in Shanxi Children's Hospital from 2014 to 2019. *J Clin Med Prac*, 2021; 25, 45–8,53. (In Chinese)
- Luo HM, Ran L, Meng L, et al. Analysis of epidemiological characteristics of report cases of rotavirus diarrhea in children under 5 years old in China, 2005-2018. *Chi J Prev Med*, 2020; 54, 181–6. (In Chinese)
- Li Y, Wang SJ, Liang F, et al. Prevalence and genetic diversity of rotavirus among children under 5 years of age in China: a meta-analysis. *Front Immunol*, 2024; 15, 1364429.
- World Health Organization. Introduction of Rotavirus vaccine. [https://immunizationdata.who.int/global/wiise-detail-page/introduction-of-rotavirus-vaccine?ISO\\_3\\_CODE=&YEAR=;2024](https://immunizationdata.who.int/global/wiise-detail-page/introduction-of-rotavirus-vaccine?ISO_3_CODE=&YEAR=;2024). [2024-05-23]
- Yuan QL, Cao ZQ, Ji WY, et al. Rotavirus vaccine coverage among children born in Beijing from 2017 to 2022. *Mod Pre Med*, 2024; 51, 2770–3. (In Chinese)
- Lu J, Guan BC, Zhang LP, et al. Rotavirus vaccine coverage in the 2013-2020 birth cohorts in Minhang district of Shanghai. *Chin J Vacc Immun*, 2021; 27, 695–9. (In Chinese)
- Ma WJ, Wei ZQ, Guo JY, et al. Effectiveness of pentavalent rotavirus vaccine in Shanghai, China: a test-negative design study. *J Pediatr*, 2023; 259, 113461.
- Huang YC, Wu FT, Huang YC, et al. Long-term effectiveness of pentavalent and monovalent rotavirus vaccines against hospitalization in Taiwan children. *Vaccine*, 2020; 38, 6435–41.
- Yi Y, Liu J, Zhang YT, et al. Effectiveness of Lanzhou lamb rotavirus vaccine and RotaTeq against hospitalized rotavirus infections among children during 2020-2023 in Guangdong Province, China: a test-negative case-control study. *Infect Dis Ther*, 2024; 13, 2301–17.
- McMurry R, Lenehan P, Awasthi S, et al. Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines. *Med*, 2021; 2, 965-78. e5.
- Bellino S, Piovesan C, Bella A, et al. Determinants of vaccination uptake, and influenza vaccine effectiveness in preventing deaths and hospital admissions in the elderly population; Treviso, Italy, 2014/2015-2016/2017 seasons. *Hum Vaccin Immunother*, 2020; 16, 301–12.
- Lee CH, Yoon HJ. Medical big data: promise and challenges. *Kidney Res Clin Pract*, 2017; 36, 3–11.
- Meng RG, Yang Y, Zhang LX. Approaches and prospects on data quality assessment of big data in health and medicine. *Chin J Health Inf Manag*, 2019; 16, 677–81. (In Chinese)
- Zimmerman RK, Patricia Nowalk M, Dauer K, et al. Vaccine effectiveness of recombinant and standard dose influenza vaccines against influenza related hospitalization using a retrospective test-negative design. *Vaccine*, 2023; 41, 5134–40.
- World Health Organization. Evaluation of COVID-19 vaccine effectiveness. [https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine\\_effectiveness-measurement-2021.1](https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine_effectiveness-measurement-2021.1). [2024-05-23]
- Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. *Lancet Infect Dis*, 2016; 16, 942–51.
- Rosa RG, Falavigna M, Manfio JL, et al. BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: a prospective test-negative design study. *Vaccine*, 2023; 41, 5461–8.
- Mujuru HA, Burnett E, Nathoo KJ, et al. Monovalent rotavirus vaccine effectiveness against rotavirus hospitalizations among children in Zimbabwe. *Clin Infect Dis*, 2019; 69, 1339–44. (In Chinese)
- World Health Organization. Generic protocol for monitoring impact of rotavirus vaccination on gastroenteritis disease burden and viral strains. <https://iris.who.int/handle/10665/69913>. [2024-05-23]
- Rogawski ET, Platts-Mills JA, Colgate ER, et al. Quantifying the impact of natural immunity on rotavirus vaccine efficacy estimates: a clinical trial in Dhaka, Bangladesh (PROVIDE) and a simulation study. *J Infect Dis*, 2018; 217, 861–8.
- World Health Organization. WHO target product profiles for COVID-19 vaccines. revised version April 2022. <https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines>. [2025-05-07]
- Ye FX, Xia LS. Sample sizes requirements for studies estimating vaccine efficacy in preventive trials. *Mod Pre Med*, 2001; 28, 31–3. (In Chinese)
- D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. *Stat Med*, 1998; 17, 2265–81.
- Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. *N Engl J Med*, 2006; 354, 23–33.
- Zaman K, Anh D D, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. *Lancet*, 2010; 37, 615–23.
- Mo ZJ, Mo Y, Li MQ, et al. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: a randomized, double-blind, placebo-controlled trial. *Vaccine*, 2017; 35, 5897–904.
- Burnett E, Parashar UD, Tate JE. Global impact of rotavirus vaccination on diarrhea hospitalizations and deaths among children <5 years old: 2006-2019. *J Infect Dis*, 2020; 222, 1731–9.
- Lin LF. Bias caused by sampling error in meta-analysis with small sample sizes. *PLoS One*, 2018; 13, e0204056.

35. Li JX, Wang H, Li DD, et al. Infection status and circulating strains of rotaviruses in Chinese children younger than 5-years old from 2011 to 2018: systematic review and meta-analysis. *Hum Vaccin Immunother*, 2021; 17, 1811–7.
36. Zhao H, Huang W, Xie WJ, et al. Pathogenic surveillance of virus diarrhea in Chongqing in 2018-2019. *J Public Health Prev Med*, 2023; 34, 68–71. (In Chinese)
37. Jiang JY, Liang D, Wang L, et al. Epidemiological surveillance: genetic diversity of rotavirus group a in the Pearl River Delta, Guangdong, China in 2019. *Biomed Environ Sci*, 2024; 37, 278–93.
38. Tian Y, Shen LY, Li WH, et al. Major changes in prevalence and genotypes of rotavirus diarrhea in Beijing, China after RV5 rotavirus vaccine introduction. *J Med Virol*, 2024; 96, e29650.
39. Zhou X, Wang YH, Chen N, et al. Surveillance of human rotaviruses in Wuhan, China (2019-2022): whole-genome analysis of emerging DS-1-like G8P[8] rotavirus. *Int J Mol Sci*, 2023; 24, 12189.
40. Naylor C, Lu M, Haque R, et al. Environmental enteropathy, oral vaccine failure and growth faltering in infants in bangladesh. *EBioMedicine*, 2015; 2, 1759–66.
41. Clark A, Tate J, Parashar U, et al. Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules. *Lancet Glob Health*, 2019; 7, e1541–52.
42. Sun ZW, Fu Y, Lu HL, et al. Association of rotavirus vaccines with reduction in rotavirus gastroenteritis in children younger than 5 years: a systematic review and meta-analysis of randomized clinical trials and observational studies. *JAMA Pediatr*, 2021; 175, e210347.
43. Cortese MM, Leblanc J, White KE, et al. Leveraging state immunization information systems to measure the effectiveness of rotavirus vaccine. *Pediatrics*, 2011; 128, e1474–81.
44. Staat MA, Payne DC, Donauer S, et al. Effectiveness of pentavalent rotavirus vaccine against severe disease. *Pediatrics*, 2011; 128, e267–75.
45. Wang FT, Mast TC, Glass RJ, et al. Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States. *Pediatr Infect Dis J*, 2013; 32, 278–83.
46. Payne DC, Selvarangan R, Azimi PH, et al. Long-term consistency in rotavirus vaccine protection: RV5 and RV1 vaccine effectiveness in US children, 2012–2013. *Clin Infect Dis*, 2015; 61, 1792–9.
47. Clark A, Van Zandvoort K, Flasche S, et al. Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials. *Lancet Infect Dis*, 2019; 19, 717–27.
48. Payne DC, Boom JA, Staat MA, et al. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011. *Clin Infect Dis*, 2013; 57, 13–20.
49. Iwata S, Nakata S, Ukae S, et al. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial. *Hum Vaccin Immunother*, 2013; 9, 1626–33.
50. Diallo AO, Wikswo ME, Sulemana I, et al. Rotavirus vaccine effectiveness against severe acute gastroenteritis: 2009-2022. *Pediatrics*, 2024; 154, e2024066879.
51. Bennett A, Pollock L, Bar-Zeev N, et al. Community transmission of rotavirus infection in a vaccinated population in Blantyre, Malawi: a prospective household cohort study. *Lancet Infect Dis*, 2021; 21, 731–40.
52. Standaert B, Strens D, Raes M, et al. Explaining the formation of a plateau in rotavirus vaccine impact on rotavirus hospitalisations in Belgium. *Vaccine*, 2022; 40, 1948–57.